Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
13.84
-0.14 (-1.00%)
At close: May 22, 2026, 4:00 PM EDT
14.00
+0.16 (1.16%)
After-hours: May 22, 2026, 4:15 PM EDT
Cullinan Therapeutics Employees
Cullinan Therapeutics had 109 employees as of December 31, 2025. The number of employees decreased by 2 or -1.80% compared to the previous year.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$2,027,881
Market Cap
850.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 109 | -2 | -1.80% | 109 | 0 |
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Xencor | 260 |
| Omeros | 175 |
| Sana Biotechnology | 142 |
| Aura Biosciences | 113 |
| ORIC Pharmaceuticals | 104 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
CGEM News
- 4 days ago - Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street - TheFly
- 5 days ago - Cullinan Therapeutics receives orphan drug designation for CLN-049 - TheFly
- 5 days ago - Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 5 days ago - Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress - GlobeNewsWire
- 16 days ago - Cullinan Therapeutics price target raised to $37 from $36 at Wedbush - TheFly
- 17 days ago - Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c) - TheFly
- 17 days ago - Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 17 days ago - Cullinan Therapeutics Quarterly report: Q1 2026 - Filings